Nitric oxide synthesis in atherosclerosis

European Heart Journal

Volumn 19, Issue 10, 1998, Pages 1504-1511

  Toutouzas, P C ^b   Tousoulis, D ^b   Davies, Graham J ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIUM DERIVED RELAXING FACTOR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR;

ARTERIOLE; ATHEROSCLEROSIS; CORONARY ARTERY; PRIORITY JOURNAL; RESISTANCE BLOOD VESSEL; REVIEW;

AGING; ANIMALS; ARTERIOSCLEROSIS; BLOOD FLOW VELOCITY; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; VASODILATION;

EID: 17944386790     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1998.1087     Document Type: Review

References (105)

1. [1] Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
2. [2] Zeiher AM, Drexler H, Wollschlager H, Just H. Endothelial dysfunction of coronary microvasculature is associated with impaired coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991; 84: 1984-92.
3. [3] Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependend vascular relaxation of patients with essential hypertension. Circulation 1993; 87: 1468-74.
4. [4] Berkenboom G, Unger P, Fang ZY, Degre S, Fontaine J. Comparison of the responses to acetylcholine and serotonin on isolated canine and human coronary arteries. Cardiovasc Res 1989; 23: 780-7.
5. [5] Panza JA, Quyyumi AA, Brush Jr JE, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-7.
6. [6] Horio Y, Yasue H, Rokutanda M et al. Effects of intracoronary injection of acetylcholine in atherosclerotic coronary arteries. Am J Cardiol 1986; 57: 984-9.
7. [7] Newman CM, Maseri A Hackett D, El-Tamimi HM, Davies GJ. Response of angiographically normal and atherosclerotic left anterior descending coronary arteries to acetylcholine. Am J Cardiol 1990; 66: 1070-6.
8. [8] Ludmer PL, Selwyn AP, Shook TL et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315: 1046-51.
9. [9] Collins P, Burman J, Chung H-I, Fox K. Hemoglobins inhibits endothelium-derived relaxation to acetylcholine in human coronary arteries in vivo. Circulation 1993; 87: 80-6.
10. [10] Crossman DC, Larkin SW, Fuller RW, Davies GJ, Maseri A. Substance P dilates epicardial coronary arteries and increases coronary blood flow in humans. Circulation 1989; 80: 475-84.
11. [11] Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333: 664-6.
12. [12] Ignaro LJ. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res 1989; 65: 1-21.
13. [13] Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-6.
14. [14] Martin W, Villani GM, Jothianandan D, Furchgott RF. Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methyl-ene blue in the rabbit aorta. J Pharmacol Exp Ther 1985; 232: 708-16.
15. [15] Rapoport RM, Murad F. Agonist-induced endothelium-dependent relaxation in rat thoracic aorta may be mediated through cruanosine monophosphate. Circ Res 1983; 52: 352-7.
16. [16] Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-5.
17. [17] Hirata Y, Yoshimi H, Takaichi S, Yanagisawa M, Masaki T. Binding and receptor down-regulation of a novel vasoconstrictor endothelin in cultured rat vascular smooth muscle cells. FEBS Let 1988; 239: 13-7.
18. [18] Hirata Y. Endothelin-1 receptors in cultured vascular smooth muscle cells and cardiocytes of rats. J Cardiovasc Pharmacol 1989; 13 (Suppl 5): 157-8.
19. [19] Rubanyi GM, Vanhoutte PM. Quabain inhibits endothelium-dependent relaxations to arachidonic acid in canine coronary arteries. J Pharmacol Exp Ther 1985; 235: 81-6.
20. [20] Boulanger C, Schini VB, Moncada S, Vanhoutte PM. Stimulation of cyclic GMP production in cultuted percine endothelial cells by bradycinin, adenosine diphospate, calcium ionophore A 23187 and nitric oxide. Br J Pharmacol 1990; 99: 176-80.
21. [21] Lüscher TF, Boulanger CM, Yang Z, Noll G, Dohi Y. Interactions between endothelium-derived relaxing and contracting factors in health and cardiovascular disease. Circulation 1993; 87 (Suppl V): V-36-V-44.
22. [22] Dohi Y, Hahn AWA, Boulanger CM, Buhler FR, Lüscher TF. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension 1992; 19: 131-7.
23. [23] Lüscher TF, Boulanger CM, Dohi Y, Yang Z. Endothelium-derived contracting factors. Hypertension 1992; 19: 117-30.
24. [24] Chu A, Chambers DE, Lin C, Kuehl WD, Cobb FR. Nitric oxide modulates epicardial coronary basal vasomotor tone in awake dogs. Am J Physiol 1990; 258: H1250-H1254.
25. [25] Nunokawa Y, Ishida N, Tanaka S. Cloning of inducible nitric oxide synthase in rat vascular smooth muscle cells. Bioch Biophys Res Commun 1993; 191: 89-94.
26. [26] Rees DD, Palmer RMJ, Hodson HF, Moncada S. A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol 1989; 96: 418-24.
27. 2+ -independent nitric oxide synthase in the myocardium. Br J Pharmacol 1992; 105: 575-80.
28. [28] Waldman SA, Murad F. Biochemical mechanisms underlying vascular smooth muscle relaxation: the granylate cyclase-cyclic GMP system. J Cardiovasc Pharmacol 1988; 12 (Suppl 5): S115-S118.
29. [29] Nava E, Palmer RMJ, Moncada S. Inhibition of nitric oxide synthesis in septic shock: how much is beneficial? Lancet 1991; 338: 1555-7.
30. [30] Forstermann U, Schmidt HW, Pollock JS et al. Isoforms of nitric oxide synthase: characterisation and purification from different cell types. Biochem Pharmacol 1991; 42: 1849-57.
31. [31] Busse R, Mulsch A, Fleming I, Hecker M. Mechanisms of nitric release from the vascular endothelium. Circulation 1993; 87 (Suppl V): V18-V25.
32. [32] Birnbaumer L. G-proteins in signal transduction. Annu Rev Pharmacol Toxicol 1990; 30: 675-705.
33. [33] Flavahan NA. G-proteins and endothelial responses. Blood Vessels 1990; 27: 218-29.
34. [34] Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-42.
35. [35] Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-12.
36. [36] Celermajer DS, Sorensen KE, Gooch VM et al. Non-invasive detection of endothelial dysfuction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-5.
37. [37] Luscher TF, Vanhoutte PM, Raij L. Antihypertensive treatment normalizes decreased endothelium-dependent relaxations in rats with salt-induced hypertension. Hypertension 1987; 9 (Suppl III): III-193-7.
38. [38] Ryan Jr TJ, Treasure CB, Yeung AC, Klein JL, Selwyn AP, Ganz P. Impaired endothelium-dependent dilation of the coronary microvasculature in patients with atherosclerosis. Circulation 1991; 84 (Suppl II): II-624.
39. [39] Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; 2: 997-1000.
40. [40] Egashira K, Hirooka Y, Kai H et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89: 2519-24.
41. [41] Casino PR, Kilcoyne CM, Quyyumi AA, Hoeg JM, Panza JA. Investigation of decreased availability of nitric oxide precursor as a mechanism responsible for impaired endothelium-dependent vasodilation in hypercholesterolemic patients. J Am Coll Cardiol 1994; 23: 844-50.
42. [42] Creager MA, Cooke JP, Mendelsohn ME et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990; 86: 228-34.
43. [43] Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992; 90: 1248-53.
44. [44] Minor RL, Myers PR, Guerra R, Bates JN, Harrison DG. Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J Clin Invest 1990; 86: 2109-16.
45. [45] Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993; 91: 2546-51.
46. [46] Linder L, Kioski W, Buhler FR, Luscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo: blunted response in essential hypertension. Circulation 1990; 81: 1762-7.
47. [47] Zeiher AM, Drexter H, Saurbier B, Just H. Endothelium-mediated coronary blood flow modulation in humans: effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 1993; 92: 652-62.
48. [48] Panza JA, Quyyumi AA, Callahan TS, Epstein SE. Effect of hypertensive treatment on endothelium-dependend vascular relaxation in patients with essential hypertension. J Am Coll Cardiol 1993; 21: 1145-51.
49. [49] Vanhoutte PM. The endothelium. Modulator of vascular smooth muscle tone. N Engl J Med 1988; 319: 512-3.
50. [50] Saito R, Nonaka S, Konishi H et al. Pharmacological properties of the tachykinin receptor subtype in endothelial cell and vasodilation. Ann NY Acad Sci 1991; 632: 457-9.
51. [51] Schiffrin EL, Deng LY, Larochelle P. Blunted effects of endothelin upon small subcutaneous resistance arteries of mild essential hypertensive patients. J Hypertens 1992; 10: 437-44.
52. [52] Salazar FJ, Alberola A, Pinilla JM, Romero JC, Quesada T. Salt-induced increase in arterila pressure during nitric oxide synthesis inhibition. Hypertension 1993; 22: 49-55.
53. [53] Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and gromerular damage. J Clin Invest 1992; 90: 278-81.
54. [54] Chen PY, Sanders PW. L-arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest 1991; 88: 1559-67.
55. [55] Nakaki T, Hishikawa K, Suzuki H, Saruta T, Kato R. L-arginine-induced hypotension. (Letter) Lancet 1990; 336: 696.
56. [56] Petros AJ, Hewlett AM, Bogle RG, Pearson JD. L-arginine-induced hypotension. Lancet (Letter) 1991; 337: 1044-5.
57. [57] Kannel WB. Update on the role of cigarette smoking in coronary artery disease. Am Heart J 1981; 101: 319-28.
58. [58] Nadler JL, Velasco JS, Horton R. Cigarette smoking inhibits prostacyclin formation. Lancet 1983; 1: 1248-50.
59. [59] Kioski W, Linder L, Stoschitzky K et al. Diminished vascular response to inhibition of endothelium-derived nitric oxide and enhanced vasoconstriction to exogenously administered endothelin-1 in clinically healthy smokers. Circulation 1994; 90: 27-34.
60. [60] Taddei S, Virdis A, Mattel P et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995; 91: 1981-7.
61. [61] Egashira K, Inou T, Hirooka Y et al. Effects of age on endothelium-dependent vasodilation of resistance coronary artery by acetylcholine in humans. Circulation 1993; 88: 77-81
62. [62] Gilligan DM, Panza JA, Kilcoyne CM, Waclawiw MA, Casino PR, Quyyumi AA. Contribution of endothelium-derived nitric oxide to exercise-induced vasodilation. Circulation 1994; 90: 2853-8.
63. [63] Vita JA, Treasure CB, Nabel EG et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990; 81: 491-7.
64. [64] Tousoulis D, Davies G, Lefroy DC, Haider AW, Crake T. Variable coronary vasomotor responses to acetylcholine in patients with normal coronary arteriograms: evidence for localised endothelial dysfunction. Heart 1996; 75: 261-6.
65. [65] Lefroy DC, Crake T, Uren NG, Davies GJ, Maseri A. Effects of inhibition of nitric oxide synthesis on epicardial coronary artery caliber and coronary blood flow in humans. Circulation 1993; 88: 43-54.
66. [66] Yasue H, Matsuyama K, Matsuyama K, Okumura K, Morikami Y, Ogawa H. Responses of angiographically normal human coronary arteries to intracoronary injection of acetylcholine by age and segment. Possible role of early atherosclerosis. Circulation 1990; 81: 482-90.
67. [67] Hodgson JMcB, Marshall J. Direct vasoconstriction and endothelium-dependent vasodilation: Mechanisms of acetylcholine effects on coronary flow and arterial diameter in patients with nonstenotic coronary arteries. Circulation 1989; 79: 1043-51.
68. [68] Tousoulis D, Davies GJ, Tentolouris C, Crake T, Lefroy DC, Toutouzas P. Effects of inhibition of nitric oxide synthesis in patients with coronary artery disease and stable angina. Eur Heart J 1997; 18: 608-13.
69. [69] Zeiher AM, Drexler H, Wollschlager H, Just H. Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991; 83: 391-401.
70. [70] El Tamimi H, Mansour M, Wargovich TJ et al. Constrictor and dilator responses to intracoronary acetylcholine in adjacent segments of the same coronary artery in patients with coronary artery disease: endothelial function revisited. Circulation 1994; 89: 45-51.
71. [71] Clarkson P, Celermajer DS, Powe AJ, Donald AE, Henry RMA, Deanfield JE. Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease. Circulation 1997; 96: 3378-83.
72. [72] Tousoulis D, Crake T, Davies G, Tentolouris C, Toutouzas P. Basal nitric oxide production by diseased coronary arteries. J Am Coll Cardiol 1994; 28: 1639.
73. [73] Tousoulis D, Davies G, Tentolouris C, Crake T, Toutouzas P. Inhibition of nitric oxide synthesis during the cold pressor test in patients with coronary artery disease. Am J Cardiol 1997; 79: 1676-9.
74. [74] Tousoulis D, Tentolouris C, Crake T, Toutouzas P, Davies G. Basal and flow-mediated nitric oxide production by atheromatous coronary arteries. J Am Coll Cardiol 1997; 29: 1256-62.
75. [75] Buttery LDK, Springall DR, Chester AH et al. Inducible NO synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest 1996; 75: 77-85.
76. [76] Van Benthuysen KM, McMurtry IF, Horwitz LD. Reperfusion after acute coronary occlusion in dogs impairs endothelium-dependent relaxation to acetylcholine and augments contractile reactivity in vitro. J Clin Invest 1987; 79: 265-74.
77. [77] Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325: 997-1001.
78. [78] Treasure CB, Klein KJ, Weintraub WS et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481-7.
79. [79] Cooke JP, Andon NA, Girerd XJ, Hirsch AT, Creager MA. Arginine restores cholinergic relaxation in hypercholesterolemic rabbit aorta. Circulation 1991; 83: 1057-62.
80. [80] Drexler H, Zeiher A, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991; 338: 1546-50.
81. [81] Tousoulis D, Davies G, Tentolouris C, Crake T, Toutouzas P. Coronary stenosis dilation induced by L-arginine. Lancet 1997; 349: 1812-3.
82. [82] Tanner FC, Noll G, Boulanger CM, Luscher TF. Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries: role of scavenger receptor and endothelium-derived nitric oxide. Circulation 1991; 83: 2012-20.
83. [83] Tsao PS, Lefer AM. Time course and mechanism of endothelial dysfunction in isolated ischemic-and hypoxicperfused rat hearts. Am J Physiol 1990; 259: H1660-H1666.
84. [84] Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 1986; 250: H822-H827.
85. [85] Bath PMW, Hassall DG, Gladwin A-M, Palmer RMJ, Martin JF. Nitric oxide and prostacyclin: divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Arterioscl Thromb 1991; 11: 254-60.
86. [86] Mao S, Yates M, Lambert L et al. Nitric oxide protects against the oxidative modification of low-density lipoprotein by macrophages. FASAB J. 1992; 6: A 1030.
87. [87] Moreyra AE, Lacy CR, Wilson AC, Kumar A, Kostis JB. Arterial blood nicotine concentration and coronary vasoconstrictive effect of low-nicotine cigarette smoking. Am Heart J 1992; 124: 392-7.
88. [88] Quillen JE, Rossen JD, Oskarsson HJ, Minor RL, Lopez AG, Winniford MD. Acute effect of cigarette smoking on the coronary circulation: constriction of epicardial and resistance vessels. J Am Coll Cardiol 1993; 22: 642-7.
89. [89] Nitenberg A, Antony I, Foult JM. Acetylcholine-induced coronary vasoconstriction in young, heavy smokers with normal coronary arteriographic findings. Am J Med 1993, 95: 71-7.
90. [90] Soltis EE. Effect of age on blood pressure and membrane-dependent vascular responses in the rat. Circ Res 1987, 61: 889-97.
91. [91] Ma XL, Weyrich AS, Lefer DJ, Lefer AM. Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. Circ Res 1993; 72: 403-12.
92. [92] Hecker M, Sessa WC, Harris HJ, Anggard EE, Vane JR. The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: Cultured endothelial cells recycle L-citrulline to L-arginine. Proc Nat Acad Sci USA 1990; 87: 8612-6.
93. [93] Nabel EG, Ganz P, Gordon JB, Alexander WR, Selwyn AP. Dilatation of normal and constriction of atherosclerotic coronary arteries caused by cold pressor test. Circulation 1988; 77: 43-52.
94. [94] Egashira K, Inou T, Hirooka Y, Yamada A, Urabe Y, Takeshita A. Evidence of impaired endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary angiograms. N Engl J Med 1993; 328: 1659-64.
95. [95] Quyyumi AA, Cannon III RO, Panza JA, Diodati JG, Epstein SE. Endothelial dysfunction in patients with chest pain and normal coronary arteries. Circulation 1992; 86: 1864-71.
96. [96] Zeiher AM, Krause T, Shachinger V, Minners J, Moser E. Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. Circulation 1995; 91: 2345-52.
97. [97] Chilian WM, Layne SM. Coronary microvascular responses to reduction in perfusion pressure. Evidence for persistent arteriolar vasomotor tone during coronary hypoperfusion. Circ Res 1990; 66: 1227-38.
98. [98] Kuo L, Davis MJ, Cannon MS, Chilian WM. Pathophysiological consequences of atherosclerosis extend into the coronary microcirculation: restoration of endothelium-dependent responses by L-arginine. Circ Res 1992; 70: 465-76.
99. [99] Sellke FW, Armstrong ML, Harrison DG. Endothelium-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic primates. Circulation 1990; 81: 1586-93.
100. [100] Quyyumi AA, Dakak N, Andrews NE, Gilligan D, Panza JA, Cannon III RA. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation 1995; 92: 320-6.
101. [101] Stamler JS, Mendelsohn ME, Amarante P et al. N-Acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor. Circ Res 1989; 65: 789-95.
102. [102] Radomski MW, Palmer RMJ, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 1987; 92: 181.
103. [103] Golino P, Piscione F, Willerson JT et al. Divergent effects of serotonin on coronary artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl J Med 1991; 324: 641-8.
104. [104] Mc Fadden EP, Clarke JG, Davies GJ, Kaski JC, Haider AW, Maseri A. Effects of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. N Engl J Med 1991; 324: 649-55.
105. [105] Yao SK, Akhtar S, Scott-Burden T et al. Endogenous and exogenous nitric oxide protect against intracoronary thrombosis and reocclusion after thrombolysis. Circulation 1995; 92: 1005-10.